Ischemic heart disease
Conditions
Interventions
Isosorbide mononitrate treatment
Untreated (control)
Sponsors
Hiroshima University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with ischemic heart disease
Exclusion criteria
Exclusion criteria: Patients with cancer Patients with stoke and/or myocardial infraction within 12 weeks of the prior to study Patients with heart failure (≥NYHA 4)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Endothelial function (FMD), endothelial progenitor cells, Rho kinase activity | — |
Countries
Japan
Contacts
Public ContactYukihito Hiagshi
Hiroshima University Hospital Division of Regenerative Medicine
Outcome results
None listed